Functional Indications of Cabozantinib

Cabozantinib (Cabozantinib) is a multi-target tyrosine kinase inhibitor that mainly blocks the angiogenesis, proliferation and metastasis of tumor cells by inhibiting multiple receptors such as VEGFR, MET, Axl and KIT. Its mechanism of action is not limited to targeting angiogenesis, but also includes inhibiting the growth and invasion of tumor cells through the MET signaling pathway, making it an effective drug for the treatment of various malignant tumors. The clinical efficacy of cabozantinib in these indications has been verified by multiple clinical trials.

1. Renal cell carcinoma (RCC): Cabozantinib was initially approved to treat renal cell carcinoma, especially in patients who have failed first-line treatments or have metastasized. It has significant anti-tumor effects by inhibiting VEGF receptors and MET receptors, reducing tumor blood supply and cell proliferation. Studies have shown that cabozantinib significantly improved patient survival and improved progression-free survival (PFS).

2. Hepatocellular carcinoma (HCC): In the treatment of hepatocellular carcinoma, cabozantinib has been approved as a second-line treatment drug. Compared with traditional sorafenib, cabozantinib is more effective in HCC patients. It effectively delays disease progression and improves patient survival by inhibiting tumor angiogenesis and promoting tumor cell apoptosis.

3. Differentiated thyroid cancer (DTC): Cabozantinib has shown strong anti-tumor effects in the treatment of differentiated thyroid cancer, especially for patients who are resistant to conventional treatments (such as radioactive iodine therapy). By inhibiting the VEGF and MET signaling pathways, cabozantinib can significantly inhibit the growth and spread of tumor cells.

4. Pancreatic neuroendocrine tumors (pNET): Cabozantinib has also shown good clinical effects in the treatment of pancreatic neuroendocrine tumors. As a multi-target therapeutic drug, cabozantinib can simultaneously inhibit multiple signaling pathways related to tumor growth and metastasis, providing a new treatment option for pNET patients.

In general, cabozantinib, as a multi-target therapeutic drug, can effectively treat a variety of refractory cancers, especially in the fields of renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer and pancreatic neuroendocrine tumors, and its clinical efficacy has been widely recognized.

Keyword tags: cabozantinib,Cabozantinib, functional indications, renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer, pancreatic neuroendocrine tumors, targeted therapy

Reference materials:https://actionkidneycancer.org/cabozantinib-most-promising-for-refractory-metastatic-kidney-cancer/